Cantor Fitzgerald restated their overweight rating on shares of Celldex Therapeutics (NASDAQ:CLDX – Free Report) in a ...
Reuters on MSN21d
Cantor Fitzgerald pays $6.75 million to settle SEC charges over misleading SPAC disclosuresWASHINGTON (Reuters) - Wall Street brokerage Cantor Fitzgerald has agreed to pay a $6.75-million penalty to settle Securities ...
CNBC on MSN21d
SEC charges Cantor Fitzgerald, led by Trump's Commerce pick, with breaking securities lawsCantor Fitzgerald CEO Howard Lutnick is co-chair of the transition team for Donald Trump. The SEC says his firm caused two ...
Cantor Fitzgerald has recently initiated ARS Pharmaceuticals Inc (SPRY) stock to Overweight rating, as announced on August 20, 2024, according to Finviz. Earlier, on August 13, 2024, Raymond James had ...
The Securities and Exchange Commission (SEC) on Thursday charged Cantor Fitzgerald L.P., a global financial services firm headed by one ...
Tripadvisor Inc Common Stock (TRIP) stock saw a modest uptick, ending the day at $14.99 which represents a slight increase of $0.22 or 1.49% from the prior close of $14.77. The stock opened at $14.9 ...
Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on 89bio (ETNB – Research Report) today and set a price target of $29.00. The ...
Cantor Fitzgerald lowered their FY2024 EPS estimates for shares of CVS Health in a report issued on Tuesday, December 31st.
After Cantor Fitzgerald got an earlier ruling from the Delaware Supreme Court finding the forfeiture-for-competition provisions of its partnership agreements valid under state law, Benjamin Nagin ...
Cantor Fitzgerald raised the firm’s price target on Axsome Therapeutics (AXSM) to $124 from $121 and keeps an Overweight rating on the shares ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback